US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 5, 2013, Pages 458-467

  Zuraw, Bruce L ^a,b   Banerji, Aleena ^c   Bernstein, Jonathan A ^d   Busse, Paula J ^e   Christiansen, Sandra C ^a,f   Davis Lorton, Mark ^g   Frank, Michael M ^h   Li, Henry H ⁱ   Lumry, William R ^j   Riedl, Marc ^k  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Allergy Department   (United States)

^g WINTHROP UNIVERSITY HOSPITAL   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Institute for Asthma and Allergy   (United States)

^j Allergy and Asthma Specialists   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bradykinin; C1 inhibitor; Hereditary angioedema; Management; On demand treatment; Prophylactic treatment

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANDROID; COMPLEMENT COMPONENT C1S INHIBITOR; DANACRINE; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ESTROGEN; FRESH FROZEN PLASMA; ICATIBANT; METHYLTESTOSTERONE; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG; SERPING1 PROTEIN, HUMAN;

ACNE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EARLY INTERVENTION; FATIGUE; FOLLOW UP; GROWTH RATE; HEALTH CARE AVAILABILITY; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIBIDO DISORDER; LIVER ADENOMA; LONG TERM CARE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MENSTRUATION DISORDER; MUSCLE CRAMP; MUSCLE INJURY; MYALGIA; NAUSEA; OBSTRUCTIVE JAUNDICE; ORTHOSTATIC HYPOTENSION; PATIENT EDUCATION; PATIENT MONITORING; PELIOSIS HEPATIS; PRACTICE GUIDELINE; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VERTIGO; VIRILIZATION; WEIGHT GAIN; ANGIOEDEMAS, HEREDITARY; DEFICIENCY;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; HUMANS; UNITED STATES;

EID: 84883344600     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.07.002     Document Type: Article

References (37)

1. Donaldson V.H., Evans R.R. Abiochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1- esterase. Am J Med 1963, 35:37-44.
2. Rosen F.S., Pensky J., Donaldson V., Charache P. Hereditary angioneurotic edema: two genetic variants. Science 1965, 148:957-958.
3. Zuraw B.L. Clinical practice. Hereditary angioedema. NEngl J Med 2008, 359:1027-1036.
4. Binkley K.E., Davis A. Clinical, biochemical, and genetic characterization of a novel estrogen- dependent inherited form of angioedema. JAllergy Clin Immunol 2000, 106:546-550.
5. Bork K., Barnstedt S.E., Koch P., Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356:213-217.
6. Frank M.M. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006, 26:653-668.
7. Frank M.M., Gelfand J.A., Atkinson J.P. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976, 84:586-593.
8. Cicardi M., Banerji A., Bracho F., Malbran A., Rosenkranz B., Riedl M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. NEngl J Med 2010, 363:532-541.
9. Cicardi M., Levy R.J., McNeil D.L., Li H.H., Sheffer A.L., Campion M., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. NEngl J Med 2010, 363:523-531.
10. Zuraw B.L., Busse P.J., White M., Jacobs J., Lumry W., Baker J., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. NEngl J Med 2010, 363:513-522.
11. Craig T.J., Levy R.J., Wasserman R.L., Bewtra A.K., Hurewitz D., Obtulowicz K., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. JAllergy Clin Immunol 2009, 124:801-808.
12. Bork K., Hardt J., Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. JAllergy Clin Immunol 2012, 130:692-697.
13. Bowen T., Cicardi M., Farkas H., Bork K., Longhurst H.J., Zuraw B., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24.
14. Craig T., Pursun E.A., Bork K., Bowen T., Boysen H., Farkas H., et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012, 5:182-199.
15. Gompels M.M., Lock R.J., Abinun M., Bethune C.A., Davies G., Grattan C., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005, 139:379-394.
16. Cicardi M., Bork K., Caballero T., Craig T., Li H.H., Longhurst H., et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012, 67:147-157.
17. Caballero T., Baeza M.L., Cabanas R., Campos A., Cimbollek S., Gomez-Traseira C., et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. JInvestig Allergol Clin Immunol 2011, 21:422-441. quiz 42-43.
18. Zuraw B.L., Bork K., Binkley K.E., Banerji A., Christiansen S.C., Castaldo A., et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012, 33(Suppl 1):S145-S156.
19. Health Literacy: A Prescription to End Confusion 2004, National Academies Press, Washington, DC. L. Nielsen-Bohlman, A.M. Panzer, D.A. Kindig (Eds.).
20. Craig T., Riedl M., Dykewicz M.S., Gower R.G., Baker J., Edelman F.J., et al. When is prophylaxis for hereditary angioedema necessary?. Ann Allergy Asthma Immunol 2009, 102:366-372.
21. Tourangeau L.M., Castaldo A.J., Davis D.K., Koziol J., Christiansen S.C., Zuraw B.L. Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012, 157:417-424.
22. Prematta M.J., Bewtra A.K., Levy R.J., Wasserman R.L., Jacobson K.W., Machnig T., et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 2012, 29:913-922.
23. Kusuma A., Relan A., Knulst A.C., Moldovan D., Zuraw B., Cicardi M., et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 2012, 125:937.e17-937.e24.
24. Frank M.M., Sergent J.S., Kane M.A., Alling D.W. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. NEngl J Med 1972, 286:808-812.
25. Gadek J.E., Hosea S.W., Gelfand J.A., Santaella M., Wickerhauser M., Triantaphyllopoulos D.C., et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. NEngl J Med 1980, 302:542-546.
26. Gelfand J.A., Sherins R.J., Alling D.W., Frank M.M. Treatment of hereditary angioedema with danazol. NEngl J Med 1976, 295:1444-1448.
27. Gadek J.E., Hosea S.W., Gelfand J.A., Frank M.M. Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. JClin Invest 1979, 64:280-286.
28. Zuraw B.L., Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012, 125:938.e1-938.e7.
29. Bork K., Hardt J., Staubach-Renz P., Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 112:58-64.
30. Yoo S.M., Khan D.A. Implantable venous access device associated complications in patients with hereditary angioedema. JAllergy Clin Immunol: In Practice 2013, 1:524-525.
31. Winnewisser J., Rossi M., Spath P., Burgi H. Type I hereditary angio-oedema. Variability of clinical presentation and course within two large kindreds. JIntern Med 1997, 241:39-46.
32. Zuraw B., Cicardi M., Levy R.J., Nuijens J.H., Relan A., Visscher S., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. JAllergy Clin Immunol 2010, 126:821-827.e14.
33. Levi M., Choi G., Picavet C., Hack C.E. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. JAllergy Clin Immunol 2006, 117:904-908.
34. Sheffer A.L., Campion M., Levy R.J., Li H.H., Horn P.T., Pullman W.E. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2double-blind, phase 3 studies. JAllergy Clin Immunol 2011, 128:153-159. e4.
35. Bork K., Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apheresis Sci 2003, 29:235-238.
36. Longhurst H.J., Farkas H., Craig T., Aygoren-Pursun E., Bethune C., Bjorkander J., et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010, 6:22.
37. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010, 6:18.